ClinicalTrials.gg
CompletedNCT05271604Updated Sep 26, 2025

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

A Phase 2 interventional study of Ozuriftamab Vedotin and Pembrolizumab in Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck and Recurrent Squamous Cell Carcinoma of the Head and Neck, sponsored by BioAtla, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-26.

Primary conditionSquamous Cell Carcinoma of Head and NeckRegistry: Head and Neck NeoplasmsReclassifiedWhy we changed it
Registry
Head and Neck Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Squamous Cell Carcinoma of Head and Neck
Why
  1. The study's listed conditions name Squamous Cell Carcinoma of Head and Neck, a narrower term within Head and Neck Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by BioAtla, Inc. · Phase 2, Interventional, and Treatment

How we know · 13 judgments

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 213 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Enrollment
483rd of 994
42 · median 41
Started
2022
with 56 others
Phase 2
359 of 1,099
58 open now
Registered
817th of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 483rd largest by enrollment of the 994 interventional ones that give a count, is one of 57 that started in 2022, is one of 359 in phase 2, and was the 817th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

213 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

208 more — sign in →

All 213 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, open-label Phase 2 study designed to evaluate the efficacy and safety of BA3021 as monotherapy and combination therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

03

Conditions studied

  • Head and Neck Cancer
  • Squamous Cell Carcinoma of Head and Neck
  • Recurrent Squamous Cell Carcinoma of the Head and Neck
  • Metastatic Cancer
  • Metastatic Squamous Cell Carcinoma of the Head and Neck

Keywords

  • Cancer
04

In context

Squamous Cell Carcinoma of Head and Neck Reclassified

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

This study's enrollment of 42 is below the median of 48 across 1,657 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Lead sponsor

BioAtla, Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Compared within Squamous Cell Carcinoma of Head and Neck, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Head and Neck Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx. Patients may not have a primary tumor site of nasopharynx (any histology).
  • /induction setting (Cohort N1): Patient with newly diagnosed Stage III SCCHN who are eligible for induction therapy with resectable tumors. No prior treatments, including surgery, radiation, or systemic treatment, for SCCHN are allowed.
  • Recurrent or setting: or cytologically confirmed recurrent or metastatic SCCHN Stage III/IV and not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy).
  • - Combination Cohorts (C1 and C2): Patients must have NO prior systemic therapy administered in the locally recurrent or metastatic setting. Previous treatments with /L1 inhibitor or anti-CTLA-4 treatment are not allowed.
  • Second-line (Combination Cohort C3) and Second-line+ (Monotherapy Cohorts M1 and M2): Patients must have documented treatment failure of no more than one approved PD-1/L1 inhibitor either administered alone or in combination.

Patients must have .

  • Age ≥ 18 years
  • Adequate renal function
  • Adequate liver function
  • Adequate hematological function
  • Have an (ECOG) performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as well as known or suspected allergy or intolerance to any agent given during this study.
  • Patients must not have known (HIV) infection, active and/or .
  • Patients must not be women who are pregnant or are breast feeding.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Cohort M1

    Monotherapy BA3021 Q2W dosing regimen

    Biological: Ozuriftamab Vedotin

  • Experimental
    Cohort M2

    Monotherapy BA3021 2Q3W dosing regimen

    Biological: Ozuriftamab Vedotin

  • Experimental
    Cohort N1

    Neoadjuvant/induction setting combination therapy of BA3021 2Q3W dosing regimen, pembrolizumab Q3W dosing regimen, and BA3071 Q3W dosing regimen prior to surgery.

    Biological: Ozuriftamab Vedotin · Biological: Pembrolizumab · Biological: Evalstotug (BA3071)

  • Experimental
    Cohort C1

    Combination therapy of BA3021 2Q3W dosing regimen, pembrolizumab Q3W dosing regimen, and BA3071 Q3W dosing regimen

    Biological: Ozuriftamab Vedotin · Biological: Pembrolizumab · Biological: Evalstotug (BA3071)

  • Experimental
    Cohort C2

    Combination therapy of BA3021 2Q3W dosing regimen, and pembrolizumab Q3W dosing regimen

    Biological: Ozuriftamab Vedotin · Biological: Pembrolizumab

  • Experimental
    Cohort C3

    Combination therapy of BA3021 2Q3W dosing regimen and cetuximab QW dosing regimen

    Biological: Ozuriftamab Vedotin · Biological: Cetuximab

Interventions

  • Conditionally active biologic anti-ROR2 antibody drug conjugate

  • BiologicalPembrolizumab

    PD-1 inhibitor

  • BiologicalEvalstotug (BA3071)

    Conditionally active biologic anti-CTLA-4 checkpoint blockade antibody

  • BiologicalCetuximab

    Epidermal growth factor receptor (EGFR) antagonist

    Also known as: Erbitux

07

What researchers measure

Primary outcomes

  1. Confirmed Objective Response Rate (ORR) per RECIST v1.1

    Proportion of patients who achieve a confirmed CR or PR according to RECIST v1.1

    Time frame: Up to 24 months

  2. Incidence of Adverse Events or Serious Adverse Events as assessed by CTCAE v5

    Measured by frequency and severity of adverse events as assessed by CTCAE v5

    Time frame: Up to 24 months

Secondary outcomes

  1. Duration of response (DOR)

    Time from the first documented OR until the first documented disease progression or death (due to any cause), whichever occurs first

    Time frame: Up to 24 months

  2. Progression-free survival (PFS)

    Time from the first dose of IP until the first documentation of disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to 24 months

  3. Best overall response (BOR)

    All post-baseline disease assessments that occur prior to the initiation of subsequent anticancer therapy

    Time frame: Up to 24 months

  4. Disease control rate (DCR)

    Proportion of patients with a best overall response of confirmed CR, confirmed PR, or stable disease (SD) ≥ 12 weeks.

    Time frame: Up to 24 months

  5. Time to response (TTR)

    Time from the first dose of investigational product until the first documentation of OR.

    Time frame: Up to 24 months

  6. Overall survival (OS)

    Time from the first dose of BA3021 treatment until death due to any cause.

    Time frame: Up to 24 months

  7. Complete response (CR)

    Proportion of patients with a best overall response of confirmed CR

    Time frame: Up to 24 months

08

Study locations

7 sites
  • USC Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Christiana Care Helen Graham Cancer Center
    Newark, Delaware 19713, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40202, United States
  • Washington University Medical Siteman Cancer Center
    St Louis, Missouri 63110, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Sep 2025, 33 months.

Of 67 industry-sponsored phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 60. This study's 33 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2022
First posted
Mar 9, 2022
StartActual
Dec 13, 2022
Primary completionActual
Sep 22, 2025
CompletionActual
Sep 22, 2025
Last update
Sep 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05271604
Lead sponsor
BioAtla, Inc.
Responsible party
Sponsor
First posted
Mar 9, 2022
Start date
Dec 13, 2022
Primary completion
Sep 22, 2025
Completion
Sep 22, 2025
Last update
Sep 26, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ozuriftamab vedotin

Start the discussion